e-learning
resources
Vienna 2003
Monday 29.09.2003
Lung cancer biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Elevated endogenous thrombin potential in patients with lung cancer
H. J. Seyfarth, A. Siegemund, T. Siegemund, T. Geike, S. Hammerschmidt, J. Schauer, H. Wirtz (Leipzig, Germany)
Source:
Annual Congress 2003 - Lung cancer biology
Session:
Lung cancer biology
Session type:
Oral Presentation
Number:
1336
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. J. Seyfarth, A. Siegemund, T. Siegemund, T. Geike, S. Hammerschmidt, J. Schauer, H. Wirtz (Leipzig, Germany). Elevated endogenous thrombin potential in patients with lung cancer. Eur Respir J 2003; 22: Suppl. 45, 1336
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 229s
Year: 2002
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Evaluation of serum levels of Sirtuin-1 in lung cancer patients
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Increased levels of plasmatic dopamine in human small cell lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Evaluation of serum tumour markers in the lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Serum tumor markers in lung cancer patients
Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies
Year: 2007
Elevated serum levels of oxidative stress biomarkers in patients with lung cancer
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003
Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker?
Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology
Year: 2008
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Source: Eur Respir J 2015; 46: 1548-1550
Year: 2015
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Plasma D-dimer level and stage of primary lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 250s
Year: 2003
A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 482s
Year: 2005
Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010
Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects
Source: Eur Respir J 2004; 24: Suppl. 48, 43s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept